Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 3.

Slides:



Advertisements
Similar presentations
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
Advertisements

10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.
The Role of Oral Antidiabetic Therapy
Diagnosis of Type 2 Diabetes 1. Glucose Testing and Interpretation: AACE Diagnostic Criteria TestResultDiagnosis FPG, mg/dL (measured after 8-hour fast)
Diabetes in Pregnancy Screening.
Lipid Disorders and Management in Diabetes
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
John B. Buse, MD, PhD Associate Professor of Medicine Chief, Division of General Medicine and Clinical Epidemiology Director, Diabetes Care Center University.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Barriers to Diabetes Control Mark E. Molitch, MD.
Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada Canadian Diabetes Association 2003.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Insulin therapy.
A1C 6.5 – 7.5% ** Monotherapy MET + GLP-1 or DPP4 1 TZD 2 Glinide or SU 5 TZD + GLP-1 or DPP4 1 MET + Colesevelam AGI Mos. *** Dual Therapy MET.
LONG TERM BENEFITS OF ORAL AGENTS
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Role of Rosuvastatin in the Treatment of Dyslipidemia
Improving Medical Management of Diabetes
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
What the GP Should Know about Diabetes Mellitus Dr. Muhieddin Omar.
Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Metabolic Syndrome Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
LDL Program Medical Management Philip E. Johnston, Pharm.D.
Practical Considerations in Clinical Management. Guideline-recommended glycemic targets in diabetes A1C (%) FPG (mg/dL) Postprandial glucose (mg/dL) ADA
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.
Therapy of Type 2 Diabetes Mellitus: UPDATE
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
SHARED MEDICAL APPOINTMENTS Achieving Better Patient Outcomes and Organizational Efficiencies Part 1 of 2 Provided as an educational service by Pfizer.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Measures of Hyperglycemia Random plasma glucose (RPG)—without regard to time of last meal Fasting plasma glucose (FPG)—before breakfast Oral glucose tolerance.
Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 2.
Glycemia Treatment Strategies Used In ACCORD
Achieving Optimal Glycaemic Control: Can Insulin Deliver?
CHANGES in ada 2015.
Copyright © 2015 by the American Osteopathic Association.
Redefining Quality Care in T2DM Patients with CV Disease
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Screening and Monitoring
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Interventions to Improve Adherence
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
RCHC’s Cardiovascular Health Initiative
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Approach to starting and adjusting insulin in type 2 diabetes.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Goals & Guidelines A summary of international guidelines for CHD
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
LecturePad Master Slide
Insulin Delivery Systems Atlanta Diabetes Associates
Hyperglycemic Targets & Hypoglycemia
Presentation transcript:

Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 3

2 Using SMAs to improve care and Profitiability  An SMA (group visit) is a periodic medical appointment held by a clinician for 90 or more minutes to provide routine or follow-up care to groups of patients  The clinician is supported by other health professionals in conducting the SMA  Private one-on-one time with the clinician is available to patients who want/need it Source: SMA Workshop, 2005; Noffsinger EB. Running Group Visits in Your Practice. 2009:4,9.

3 Patients Suited to SMAs  SMAs are well-suited to: –Patients with chronic conditions –High utilizers –Those with extensive emotional, informational, or psychosocial needs –Patients having difficulty making behavioral/ lifestyle changes—eg, smoking cessation, medication adherence  Source: AAFP Web site. Group visits: introduction:1; Schmucker D. Group Medical Appointments. 2006:85.

4  Cooperative Health Care Clinic (CHCC)  Drop-in Group Medical Appointment (DIGMA)  SMA for Physical Exams (Physicals SMA) Types of SMAs Source: SMA Workshop, 2005; Noffsinger EB. Running Group Visits in Your Practice. 2009:122.

5 Privacy Issues  Anything patients say about themselves is not of concern regarding HIPAA –HIPAA requires written consent before providers disclose patients’ personal information  Patients sign privacy notice when entering meeting or exam room  Oral privacy reminders are given at the beginning of each SMA  Private time is available with the physician Sources: Schmucker D. Group Medical Appointments. 2006: ; SMA Workshop, 2005; Noffsinger EB. Running Group Visits in Your Practice. 2009:9.

6 SMA Benefits  SMAs offer: –More time and a more relaxed pace of care –Increased patient education –Peer support and encouragement –The opportunity to identify psychosocial issues or previously unnoticed medical issues –Care delivered by a team –Opportunity for family/caregivers to participate –Better customer focus –Better Profitability Source: SMA Workshop, 2005; Noffsinger EB. Running Group Visits in Your Practice. 2009:9,12.

Strategic Use of Medications: Treatment Goals ADA Guidelines a1 A1C<7% FPG≤ mg/dL 2-hour PPG <180 mg/dL Patient with Diabetes and CVD Glycemic Control Lipid Management 1. American Diabetes Association. Diabetes Care. 2009;32(suppl 1):S13-S NCEP Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106(25): Grundy SM, et al. Circulation. 2004;110: Rodbard HW, et al. Endocr Pract. 2007;13(suppl 1):1-68. a For most nonpregnant adults with diabetes; individualized goals are endorsed, with less stringent control for those with more advanced disease or history of severe hypoglycemia ADA = American Diabetes Association; A1C=glycosylated hemoglobin; FPG = fasting plasma glucose: PPG=postprandial glucose LDL-C Goals (NCEP ATP III, 2,3 ADA, 1 and AACE 4) LDL-C<100 mg/dL <70 mg/dL (optional goal for patients with diabetes and CVD) 30% to 40% reduction in those uncontrolled on maximally tolerated statin doses 4

Current Therapy Intervention 6.5 to 8.5 Continue Lifestyle Modification Monitor/adjust Rx to maintain ACE Glycemic Goals † Monotherapy : Glinides, SU, AGI, metformin, TZD, DPP-4, premixed insulin preparations a, prandial b or basal insulin c Continuous Titration of Rx (2-3 months) Combination Therapy: Glinides, SU, DPP-4, AGI, metformin, TZD, colesevelam, incretin mimetic*, premixed insulin preparations a, prandial 2 or basal insulin c Intensify Lifestyle Modification Maximize Combination Therapy Maximize Insulin Therapy Monitor/adjust Rx to maintain ACE Glycemic Goals † Intensify Lifestyle Modification Initiate Combination Therapy Incretin mimetic + metformin and/or TZD Basal c or premixed insulin preparations a Amylin analog** with prandial insulin b Metformin + SU or Glinide Metformin + TZD d,e or AGI TZD + SU DPP-4 + Metformin ± SU DPP-4 + TZD Colesevelam + met, SU or insulin Incretin mimetic* + metformin and/or SU Other approved combinations including approved oral agents with insulin f If elevated FPG, add or increase basal insulin c If elevated PPG, add or increase prandial insulin b If elevated FPG and PPG, add or intensify basal c + prandial b or premixed insulin therapy a Combine with approved oral agents f Amylin analog** with prandial insulin b Add incretin mimetic to patients on SU, TZD, and/or metformin Continuous Titration of Rx (2-3 months) Road Map to Achieve Glycemic Goals: Welchol ® (colesevelam HCl) Is Indicated for Patients With Diabetes † ACE Glycemic Goals ≤ 6.5% A1C <110 mg/dL FPG <110 mg/dL preprandial <140 mg/dL 2-hr PPG *Available as exenatide **Available as pramlintide aAnalog preparations preferred bPrandial insulin (rapid-acting insulin analogs available as lispro, aspart, glulisine, or regular insulin) can be added to any therapeutic intervention at any time to address persistent postprandial hyperglycemia cAvailable as glargine and detemir dA recent meta-analysis suggests a possible link of rosiglitazone to cardiovascular events; other studies do not confirm or exclude this risk. TheFDA has stated “In their entirety, the available data on the risk of myocardial infarction are inconclusive.” eCannot be used in NYHA CHF Class 3 or 4 fAccording to the FDA, rosiglitazone not recommended with insulin ACE/AACE Diabetes Road Map Task Force. April 2008 Revision. Accessed March 23, Curre nt A1C% colesevelam

Summary  Diabetes is a highly prevalent and costly disease in the US population –Most patients with diabetes have elevated LDL-C –Patients with diabetes have at least a twofold increase in risk of heart disease compared with people without diabetes –Cost increases with severity of CVD risk factors  Patients with comorbid diabetes and dyslipidemia need comprehensive care to lower their risk of CHD and complications  Potentially cost-effective strategies for managing comorbid diabetes and dyslipidemia include –Targeting high-risk patients for intervention –Use of collaborative care programs using nurse and/or pharmacist case managers to direct care –Use of SMA’s to improve patient care and profitability –Appropriate use of medications to achieve glycemic and lipid control